Is risk of central nervous system (CNS) relapse related to adjuvant taxane treatment in node-positive breast cancer? Results of the CNS substudy in the intergroup phase III BIG 02-98 trialPESTALOZZI, B. C; FRANCIS, P; GNANT, M et al.Annals of oncology. 2008, Vol 19, Num 11, pp 1837-1841, issn 0923-7534, 5 p.Article

Governing features of the stability of colluvium slopes over basaltPERAZZOLO, L; BICA, A. V. D; BRESSANI, L. A et al.International Symposium on Landslides. 2004, pp 993-998, isbn 04-1535-667-9, 6 p.Conference Paper

HER-2 overexpression/amplification and its interaction with taxane-based therapy in breast cancerAZAMBUJA, E; DURBECQ, V; ROSA, D. D et al.Annals of oncology. 2008, Vol 19, Num 2, pp 223-232, issn 0923-7534, 10 p.Article

Proliferative markers as prognostic and predictive tools in early breast cancer : where are we now?COLOZZA, M; AZAMBUJA, E; CARDOSO, F et al.Annals of oncology. 2005, Vol 16, Num 11, pp 1723-1739, issn 0923-7534, 17 p.Article

Geotechnical properties of a residual soil of gneiss for soil nailing designBERNARDES, J. A; GOBBI, F; BICA, A. V. D et al.International Symposium on Landslides. 2004, pp 1665-1670, isbn 04-1535-667-9, 6 p.Conference Paper

Discrepancies in cancer incidence and mortality and its relationship to health expenditure in the 27 European Union member statesADES, F; SENTERRE, C; DE AZAMBUJA, E et al.Annals of oncology. 2013, Vol 24, Num 11, pp 2897-2902, issn 0923-7534, 6 p.Article

The landscape of medical oncology in Europe by 2020DE AZAMBUJA, E; AMEYE, L; PAESMANS, M et al.Annals of oncology. 2014, Vol 25, Num 2, pp 525-528, issn 0923-7534, 4 p.Article

Long-term toxic effects of adjuvant chemotherapy in breast cancerAZIM, H. A; DE AZAMBUJA, E; COLOZZA, M et al.Annals of oncology. 2011, Vol 22, Num 9, pp 1939-1947, issn 0923-7534, 9 p.Article

Pertuzumab: new hope for patients with HER2-positive breast cancerCAPELAN, M; PUGLIANO, L; DE AZAMBUJA, E et al.Annals of oncology. 2013, Vol 24, Num 2, pp 273-282, issn 0923-7534, 10 p.Article

Controversial issues in early-stage breast cancer: a global collaborative survey, supported by the European Society for Medical Oncology (ESMO)ZARDAVAS, D; ADES, F; SPASOJEVIC, I. B et al.Annals of oncology. 2014, Vol 25, Num 8, pp 1558-1562, issn 0923-7534, 5 p.Article

Factors associated with surgical management following neoadjuvant therapy in patients with primary HER2-positive breast cancer: results from the NeoALTTO phase III trialCRISCITIELLO, C; AZIM, H. A; AGBOR-TARH, D et al.Annals of oncology. 2013, Vol 24, Num 8, pp 1980-1985, issn 0923-7534, 6 p.Article

Ki-67 as prognostic marker in early breast cancer: A meta-analysis of published studies involving 12 155 patientsDE AZAMBUJA, E; CARDOSO, F; DE CASTRO JR, G et al.British journal of cancer. 2007, Vol 96, Num 10, pp 1504-1513, issn 0007-0920, 10 p.Article

Use of adjuvant chemotherapy (CT) and radiotherapy (RT) in incompletely resected (R1) early stage Non-Small Cell Lung Cancer (NSCLC): A European survey conducted by the European Society for Medical Oncology (ESMO) Young Oncologists CommitteeCALIFANO, R; KARAMOUZIS, M. V; POSTEL-VINAY, S et al.Lung cancer. 2014, Vol 85, Num 1, pp 74-80, issn 0169-5002, 7 p.Article

Role of the multidisciplinary team in breast cancer management: results from a large international survey involving 39 countriesSAINI, K. S; TAYLOR, C; PAESMANS, M et al.Annals of oncology. 2012, Vol 23, Num 4, pp 853-859, issn 0923-7534, 7 p.Article

Phase I trial combining temozolomide plus lapatinib for the treatment of brain metastases in patients with HER2-positive metastatic breast cancer: the LAPTEM trialDE AZAMBUJA, E; ZARDAVAS, D; SOTIRIOU, C et al.Annals of oncology. 2013, Vol 24, Num 12, pp 2985-2989, issn 0923-7534, 5 p.Article

Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice GuidelinesCURIGLIANO, G; CARDINALE, D; SUTER, T et al.Annals of oncology. 2012, Vol 23, issn 0923-7534, vii155-vii166, SUP7Article

Overall survival benefit for sequential doxorubicin―docetaxel compared with concurrent doxorubicin and docetaxel in node-positive breast cancer—8—year results of the Breast International Group 02-98 phase III trialOAKMAN, C; FRANCIS, P. A; THÜRLIMANN, B et al.Annals of oncology. 2013, Vol 24, Num 5, pp 1203-1211, issn 0923-7534, 9 p.Article

Genomic grade adds prognostic value in invasive lobular carcinomatMETZGER-FILHO, O; MICHIELS, S; HUSSY, S et al.Annals of oncology. 2013, Vol 24, Num 2, pp 377-384, issn 0923-7534, 8 p.Article

Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trialUNTCH, M; GELBER, R. D; DE AZAMBUJA, E et al.Annals of oncology. 2008, Vol 19, Num 6, pp 1090-1096, issn 0923-7534, 7 p.Article